This company listing is no longer active
BCEL Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Atreca, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.09 |
| 52 Week High | US$1.18 |
| 52 Week Low | US$0.052 |
| Beta | 1.03 |
| 1 Month Change | -2.17% |
| 3 Month Change | -40.00% |
| 1 Year Change | -92.17% |
| 3 Year Change | -98.85% |
| 5 Year Change | -99.47% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jul 23
Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?
Dec 08Atreca GAAP EPS of -$0.72 misses by $0.02
Aug 08Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jun 18Atreca: Biotech With Promise Based On First Candidate ATRC-101
Apr 22Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Mar 05Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
Jan 25Atreca: Safety Data Brought Down Stock
Sep 10Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Sep 02We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
May 14Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares
Jan 29We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
Dec 07
Atreca EPS misses by $0.06
Nov 12Shareholder Returns
| BCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 0.8% |
| 1Y | -92.2% | -2.7% | 22.4% |
Return vs Industry: BCEL underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: BCEL underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| BCEL volatility | |
|---|---|
| BCEL Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCEL's share price has been volatile over the past 3 months.
Volatility Over Time: BCEL's weekly volatility has decreased from 29% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 90 | John Orwin | www.atreca.com |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.
Atreca, Inc. Fundamentals Summary
| BCEL fundamental statistics | |
|---|---|
| Market cap | US$3.57m |
| Earnings (TTM) | -US$97.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs BCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCEL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$97.76m |
| Earnings | -US$97.76m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/16 14:43 |
| End of Day Share Price | 2024/06/14 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atreca, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Kumaraguru Raja | Brookline Capital Markets |
| John Newman | Canaccord Genuity |